lifitegrast indications/contra

Stem definitionDrug idCAS RN
integrin antagonists 5174 1025967-78-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • lifitegrast
  • SAR 1118-023
  • SAR 1118
  • SAR-1118
  • xiidra
a lymphocyte function-associated antigen-1 ( LFA-1) antagonist, blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1), LFA-1/ICAM-1 interaction can contribute to the formation of an immunological synapse resulting in T-cell activation and migration to target tissues
  • Molecular weight: 615.48
  • Formula: C29H24Cl2N2O7S
  • CLOGP: 2.28
  • LIPINSKI: 1
  • HAC: 9
  • HDO: 2
  • TPSA: 133.99
  • ALOGS: -5.03
  • ROTB: 7

Drug dosage:

None

Approvals:

DateAgencyCompanyOrphan
July 11, 2016 FDA SHIRE DEV LLC

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Instillation site pain 1396.62 126.02 149 317 123 3385270
Instillation site reaction 913.21 126.02 93 373 8 3385385
Vision blurred 435.01 126.02 95 371 19494 3365899
Dysgeusia 334.73 126.02 70 396 11354 3374039
Eye irritation 284.07 126.02 52 414 4147 3381246
Instillation site irritation 282.67 126.02 30 436 15 3385378
Product quality issue 240.83 126.02 63 403 26672 3358721
Instillation site erythema 201.27 126.02 22 444 21 3385372
Ocular hyperaemia 163.68 126.02 34 432 5119 3380274
Lacrimation increased 159.43 126.02 31 435 3337 3382056
Instillation site pruritus 140.76 126.02 15 451 8 3385385
Eye discharge 131.08 126.02 22 444 1024 3384369
Instillation site lacrimation 126.55 126.02 13 453 1 3385392

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC S01XA25 SENSORY ORGANS
OPHTHALMOLOGICALS
OTHER OPHTHALMOLOGICALS
Other ophthalmologicals
CHEBI has role CHEBI:35472 anti-inflammatory drug
FDA EPC N0000192701 Lymphocyte Function-Associated Antigen-1 Antagonist
FDA MoA N0000192700 Lymphocyte Function-Associated Antigen-1 Antagonists
MeSH PA D009883 Ophthalmic Solutions
MeSH PA D019999 Pharmaceutical Solutions

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Tear film insufficiency indication 46152009 DOID:10140

Acid dissociation constants calculated using MoKa v3.0.0

scroll-->
Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.42 acidic
pKa2 12.3 acidic

Orange Book patent data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
5% XIIDRA SHIRE DEV LLC N208073 July 11, 2016 RX SOLUTION/DROPS OPHTHALMIC 7745460 Nov. 5, 2024 TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
5% XIIDRA SHIRE DEV LLC N208073 July 11, 2016 RX SOLUTION/DROPS OPHTHALMIC 7790743 Nov. 5, 2024 TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
5% XIIDRA SHIRE DEV LLC N208073 July 11, 2016 RX SOLUTION/DROPS OPHTHALMIC 8592450 May 17, 2026 TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
5% XIIDRA SHIRE DEV LLC N208073 July 11, 2016 RX SOLUTION/DROPS OPHTHALMIC 8367701 April 15, 2029 TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
5% XIIDRA SHIRE DEV LLC N208073 July 11, 2016 RX SOLUTION/DROPS OPHTHALMIC 9447077 April 15, 2029 TREATMENT OF THE SIGNS SYMPTOMS OF DRY EYE DISEASE (DED)
5% XIIDRA SHIRE DEV LLC N208073 July 11, 2016 RX SOLUTION/DROPS OPHTHALMIC 8168655 May 9, 2029 TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)

Orange Book exclusivity data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
5% XIIDRA SHIRE DEV LLC N208073 July 11, 2016 RX SOLUTION/DROPS OPHTHALMIC July 11, 2021 NEW CHEMICAL ENTITY

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Integrin alpha-L/beta-2 Adhesion ANTAGONIST IC50 8.05 SCIENTIFIC LITERATURE DRUG LABEL
Intercellular adhesion molecule 1 Unclassified IC50 8.53 CHEMBL

External reference:

scroll-->
IDSource
CHEBI:133023 CHEBI
7533 IUPHAR_LIGAND_ID
D10374 KEGG_DRUG
038E5L962W UNII
9584 INN_ID
1801820 RXNORM
016935 NDDF
4035938 VANDF
31873 MMSL
N0000192706 NDFRT
CHEMBL2048028 ChEMBL_ID
CHEMBL2048409 ChEMBL_ID
C575157 MESH_SUPPLEMENTAL_RECORD_UI
DB11611 DRUGBANK_ID
11965427 PUBCHEM_CID

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
Xiidra HUMAN PRESCRIPTION DRUG LABEL 1 54092-606 SOLUTION/ DROPS 50 mg OPHTHALMIC NDA 16 sections